Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study

HepatitisHepatology

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

J Hepatol.

Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A

doi: 10.1016/j.jhep.2018.03.009.

Hepatitis

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

J Hepatol.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW

doi: 10.1016/j.jhep.2019.04.016.

HepatitisHepatology

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

J Hepatol.

Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Estivill Mercade G, Kho D, Petoumenos K, Marks P, Tatsch F, Gabriela Pires Dos Santos A, Gane E, SMART-C Study Group.

doi: 10.1016/j.jhep.2019.10.010.

Hepatitis

Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals

J Infect Dis.

Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.

doi: 10.1093/infdis/jiaa359.

HepatitisHepatology

Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis

J Viral Hepat.

Masetti C, Lionetti , Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'Unto C, Francioso S, Brega A, Montalbano M, Visco-Comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'Offizi G, Gasbarrini A, De Santis A, Angelico M

doi: 10.1111/jvh.12982.

HepatitisHepatology

Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection

J Gastroenterol Hepatol.

Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y

doi: 10.1111/jgh.14991.

Hepatitis

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-acting Antiviral Agents

Clin Gastroenterol Hepatol.

Mendizabal M, Piñero F, Ridruejo E, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M

doi: 10.1016/j.cgh.2020.02.044.

Hepatitis

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study

Lancet Gastroenterol Hepatol.

Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A

doi: 10.1016/S2468-1253(20)30081-9.

Hepatitis

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study

Lancet Gastroenterol Hepatol

Hajarizadeh B, Grebely J, Byrne M, Marks P, Amin J, McManus H, Butler T, Cunningham EB, Vickerman P, Martin NK, McHutchison JG, Brainard DM, Treloar C, Chambers GM, Grant L, Mcgrath C, Lloyd AR, Dore GJ, SToP-C study group.

doi: 10.1016/S2468-1253(21)00077-7

Related content

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals

Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis

Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-acting Antiviral Agents

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study